Gene based therapy for sickle cell disease in low and middle income countries insights from the Gambia

Abstract Sickle Cell Disease (SCD) remains a significant global health burden, disproportionately affecting low- and middle-income countries (LMICs), particularly in sub-Saharan Africa. Recent advancements in gene-based therapies, including CRISPR-Cas9 technologies like Casgevy and lentiviral treatm...

Descrición completa

Detalles Bibliográficos

Principais autores:	Rangarirai Makuku, Fiona McGowan Martha Hutton, Leander Penaso Marquez, Sunny O. Abarikwu, Marcarious M. Tantuoyir, Muhammed Camara, Momodou S. Jallow, Ernest Moyo, Lindelwa Phakamile Mmema, Michael P. K. Mendy, Kelvin Thomas, Emmanuel Lawal
Formato:	Artigo
Idioma:	Inglês
Publicado:	Springer 2026-05-01
Series:	Discover Public Health
Assuntos:	Sickle cell disease Gene therapy CRISPR-Cas9 Global health equity Low- and Middle-Income Countries (LMICs) Casgevy
Acceso en liña:	https://doi.org/10.1186/s12982-026-01970-7
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!